EFFECTS OF RN316 (PF-04950615), A HUMANIZED IGG2[delta]A MONOCLONAL ANTIBODY BINDING PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9, ON LIPOPROTEIN PARTICLES IN HYPERCHOLESTEROLEMIC SUBJECTS
Day 36a (Study #1) Day 71a (Study #2 and #3) RN316 Groups (Number of subjectse) Placebo (n=12) 0.25 mg/kg (n=13) 0.5 mg/kg (n=13) 1 mg/kg (n=12) 1.5 mg/kg (n=14) Placebof (n=31) 0.25 mg/kg (n=14) 1 mg/kgf (n=32) 3 mg/kgf (n=33) 6 mg/kg (n=15) VLDL/Chylomicron Particles (nmol/L) 32.4c -7.6d -51.3cd -...
Gespeichert in:
| Veröffentlicht in: | Journal of the American College of Cardiology 2013-03, Vol.61 (10), p.E1387 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 10 |
| container_start_page | E1387 |
| container_title | Journal of the American College of Cardiology |
| container_volume | 61 |
| creator | Wan, Hong Gumbiner, Barry Joh, Tenshang Udata, Chandrasekhar gues, Philippe Garzone, Pamela D |
| description | Day 36a (Study #1) Day 71a (Study #2 and #3) RN316 Groups (Number of subjectse) Placebo (n=12) 0.25 mg/kg (n=13) 0.5 mg/kg (n=13) 1 mg/kg (n=12) 1.5 mg/kg (n=14) Placebof (n=31) 0.25 mg/kg (n=14) 1 mg/kgf (n=32) 3 mg/kgf (n=33) 6 mg/kg (n=15) VLDL/Chylomicron Particles (nmol/L) 32.4c -7.6d -51.3cd -32.8cd -44.3cd -11.9 44.4 -0.74 -31.1 -31.0 LDL Particles (nmol/L) -1.3 -17.8cd -51.2cd -56.6cd -59.0cd 0.2 -12.4 -44.6cd -47.3cd -57.4cd Small LDL Particles (nmol/L) 8.5 -9.3 -57.6cd -50.9cd -68.5cd 14.3 -13.1d -42.1cd -54.6cd -58.8cd HDL Particles (umol/L) 3.9 11.1c 8.3c 9.3c 14.8cd -0.8 0.9 5.8cd 9.5cd 11.9cd VLDL Particle Size (nm) 7.8 7.5 12.1c 15.6c 12.4c 9.1c 3.9 1.4d 4.8 10.2c HDL Particle Size (nm) 0.6 0.8 1.0 1.8c 1.5c -0.5 0.3 0.8cd 1.0cd 0.3 LDL Particle Size (nm) -1.2 -0.4 1.6cd 0.3 1.1d -0.8 0.7 1.5cd 2.1cd 2.8cd a. Day 36 and Day 71 were two weeks after last dose in respective studies; b. obtained from ANCOVA model on the CFB with baseline levels as an covariant and treatment as a factor; c. p-Value for % CFB < 0.05; d. p-Value for % CFB vs Placebo < 0.05; e. Number of treated subjects with both baseline and Day 36 or Day 71 data available for analysis; f. Pooled data from Study #2 and #3. |
| doi_str_mv | 10.1016/S0735-1097(13)61387-X |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1673886287</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3657613811</sourcerecordid><originalsourceid>FETCH-proquest_journals_16738862873</originalsourceid><addsrcrecordid>eNqNjt9KwzAUxoMoWP88gnDAmw1WTRaTtpdZmrbRNiltJpsiY2C9GMPpuj2e72YGsmvhcD6-c37f4SB0Q_AdwYTftziiLCQ4iQaEDjmhcRTOTlBAGItDypLoFAVH5Bxd9P0KY8xjkgToR2WZkq4Fm0FjKOEwqLMQPyQMc8KGIxBQTCth9ItKQef5-PW9W--WbwIqa6wsrRElCOP0xKZzmGiTapND3VhfTmkD0ppn1TjRKminE6dL3frpk5r57ua1gmQE1kCp62OkFo3TslQteFN4ppGF9dapxkul5eHS4-HrK3T2sVz33fWfXqLbTDlZhF_bzfe-63eL1Wa__fSrBeERjWM-jiP6P-oXVHtcRg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1673886287</pqid></control><display><type>article</type><title>EFFECTS OF RN316 (PF-04950615), A HUMANIZED IGG2[delta]A MONOCLONAL ANTIBODY BINDING PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9, ON LIPOPROTEIN PARTICLES IN HYPERCHOLESTEROLEMIC SUBJECTS</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via ScienceDirect (Elsevier)</source><source>Alma/SFX Local Collection</source><creator>Wan, Hong ; Gumbiner, Barry ; Joh, Tenshang ; Udata, Chandrasekhar ; gues, Philippe ; Garzone, Pamela D</creator><creatorcontrib>Wan, Hong ; Gumbiner, Barry ; Joh, Tenshang ; Udata, Chandrasekhar ; gues, Philippe ; Garzone, Pamela D</creatorcontrib><description>Day 36a (Study #1) Day 71a (Study #2 and #3) RN316 Groups (Number of subjectse) Placebo (n=12) 0.25 mg/kg (n=13) 0.5 mg/kg (n=13) 1 mg/kg (n=12) 1.5 mg/kg (n=14) Placebof (n=31) 0.25 mg/kg (n=14) 1 mg/kgf (n=32) 3 mg/kgf (n=33) 6 mg/kg (n=15) VLDL/Chylomicron Particles (nmol/L) 32.4c -7.6d -51.3cd -32.8cd -44.3cd -11.9 44.4 -0.74 -31.1 -31.0 LDL Particles (nmol/L) -1.3 -17.8cd -51.2cd -56.6cd -59.0cd 0.2 -12.4 -44.6cd -47.3cd -57.4cd Small LDL Particles (nmol/L) 8.5 -9.3 -57.6cd -50.9cd -68.5cd 14.3 -13.1d -42.1cd -54.6cd -58.8cd HDL Particles (umol/L) 3.9 11.1c 8.3c 9.3c 14.8cd -0.8 0.9 5.8cd 9.5cd 11.9cd VLDL Particle Size (nm) 7.8 7.5 12.1c 15.6c 12.4c 9.1c 3.9 1.4d 4.8 10.2c HDL Particle Size (nm) 0.6 0.8 1.0 1.8c 1.5c -0.5 0.3 0.8cd 1.0cd 0.3 LDL Particle Size (nm) -1.2 -0.4 1.6cd 0.3 1.1d -0.8 0.7 1.5cd 2.1cd 2.8cd a. Day 36 and Day 71 were two weeks after last dose in respective studies; b. obtained from ANCOVA model on the CFB with baseline levels as an covariant and treatment as a factor; c. p-Value for % CFB < 0.05; d. p-Value for % CFB vs Placebo < 0.05; e. Number of treated subjects with both baseline and Day 36 or Day 71 data available for analysis; f. Pooled data from Study #2 and #3.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/S0735-1097(13)61387-X</identifier><language>eng</language><publisher>New York: Elsevier Limited</publisher><subject>Atoms & subatomic particles ; Cardiology ; Cholesterol ; Low density lipoprotein ; Particle size ; Studies</subject><ispartof>Journal of the American College of Cardiology, 2013-03, Vol.61 (10), p.E1387</ispartof><rights>Copyright Elsevier Limited Mar 12, 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Wan, Hong</creatorcontrib><creatorcontrib>Gumbiner, Barry</creatorcontrib><creatorcontrib>Joh, Tenshang</creatorcontrib><creatorcontrib>Udata, Chandrasekhar</creatorcontrib><creatorcontrib>gues, Philippe</creatorcontrib><creatorcontrib>Garzone, Pamela D</creatorcontrib><title>EFFECTS OF RN316 (PF-04950615), A HUMANIZED IGG2[delta]A MONOCLONAL ANTIBODY BINDING PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9, ON LIPOPROTEIN PARTICLES IN HYPERCHOLESTEROLEMIC SUBJECTS</title><title>Journal of the American College of Cardiology</title><description>Day 36a (Study #1) Day 71a (Study #2 and #3) RN316 Groups (Number of subjectse) Placebo (n=12) 0.25 mg/kg (n=13) 0.5 mg/kg (n=13) 1 mg/kg (n=12) 1.5 mg/kg (n=14) Placebof (n=31) 0.25 mg/kg (n=14) 1 mg/kgf (n=32) 3 mg/kgf (n=33) 6 mg/kg (n=15) VLDL/Chylomicron Particles (nmol/L) 32.4c -7.6d -51.3cd -32.8cd -44.3cd -11.9 44.4 -0.74 -31.1 -31.0 LDL Particles (nmol/L) -1.3 -17.8cd -51.2cd -56.6cd -59.0cd 0.2 -12.4 -44.6cd -47.3cd -57.4cd Small LDL Particles (nmol/L) 8.5 -9.3 -57.6cd -50.9cd -68.5cd 14.3 -13.1d -42.1cd -54.6cd -58.8cd HDL Particles (umol/L) 3.9 11.1c 8.3c 9.3c 14.8cd -0.8 0.9 5.8cd 9.5cd 11.9cd VLDL Particle Size (nm) 7.8 7.5 12.1c 15.6c 12.4c 9.1c 3.9 1.4d 4.8 10.2c HDL Particle Size (nm) 0.6 0.8 1.0 1.8c 1.5c -0.5 0.3 0.8cd 1.0cd 0.3 LDL Particle Size (nm) -1.2 -0.4 1.6cd 0.3 1.1d -0.8 0.7 1.5cd 2.1cd 2.8cd a. Day 36 and Day 71 were two weeks after last dose in respective studies; b. obtained from ANCOVA model on the CFB with baseline levels as an covariant and treatment as a factor; c. p-Value for % CFB < 0.05; d. p-Value for % CFB vs Placebo < 0.05; e. Number of treated subjects with both baseline and Day 36 or Day 71 data available for analysis; f. Pooled data from Study #2 and #3.</description><subject>Atoms & subatomic particles</subject><subject>Cardiology</subject><subject>Cholesterol</subject><subject>Low density lipoprotein</subject><subject>Particle size</subject><subject>Studies</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqNjt9KwzAUxoMoWP88gnDAmw1WTRaTtpdZmrbRNiltJpsiY2C9GMPpuj2e72YGsmvhcD6-c37f4SB0Q_AdwYTftziiLCQ4iQaEDjmhcRTOTlBAGItDypLoFAVH5Bxd9P0KY8xjkgToR2WZkq4Fm0FjKOEwqLMQPyQMc8KGIxBQTCth9ItKQef5-PW9W--WbwIqa6wsrRElCOP0xKZzmGiTapND3VhfTmkD0ppn1TjRKminE6dL3frpk5r57ua1gmQE1kCp62OkFo3TslQteFN4ppGF9dapxkul5eHS4-HrK3T2sVz33fWfXqLbTDlZhF_bzfe-63eL1Wa__fSrBeERjWM-jiP6P-oXVHtcRg</recordid><startdate>20130312</startdate><enddate>20130312</enddate><creator>Wan, Hong</creator><creator>Gumbiner, Barry</creator><creator>Joh, Tenshang</creator><creator>Udata, Chandrasekhar</creator><creator>gues, Philippe</creator><creator>Garzone, Pamela D</creator><general>Elsevier Limited</general><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20130312</creationdate><title>EFFECTS OF RN316 (PF-04950615), A HUMANIZED IGG2[delta]A MONOCLONAL ANTIBODY BINDING PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9, ON LIPOPROTEIN PARTICLES IN HYPERCHOLESTEROLEMIC SUBJECTS</title><author>Wan, Hong ; Gumbiner, Barry ; Joh, Tenshang ; Udata, Chandrasekhar ; gues, Philippe ; Garzone, Pamela D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_16738862873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Atoms & subatomic particles</topic><topic>Cardiology</topic><topic>Cholesterol</topic><topic>Low density lipoprotein</topic><topic>Particle size</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wan, Hong</creatorcontrib><creatorcontrib>Gumbiner, Barry</creatorcontrib><creatorcontrib>Joh, Tenshang</creatorcontrib><creatorcontrib>Udata, Chandrasekhar</creatorcontrib><creatorcontrib>gues, Philippe</creatorcontrib><creatorcontrib>Garzone, Pamela D</creatorcontrib><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wan, Hong</au><au>Gumbiner, Barry</au><au>Joh, Tenshang</au><au>Udata, Chandrasekhar</au><au>gues, Philippe</au><au>Garzone, Pamela D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>EFFECTS OF RN316 (PF-04950615), A HUMANIZED IGG2[delta]A MONOCLONAL ANTIBODY BINDING PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9, ON LIPOPROTEIN PARTICLES IN HYPERCHOLESTEROLEMIC SUBJECTS</atitle><jtitle>Journal of the American College of Cardiology</jtitle><date>2013-03-12</date><risdate>2013</risdate><volume>61</volume><issue>10</issue><spage>E1387</spage><pages>E1387-</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><abstract>Day 36a (Study #1) Day 71a (Study #2 and #3) RN316 Groups (Number of subjectse) Placebo (n=12) 0.25 mg/kg (n=13) 0.5 mg/kg (n=13) 1 mg/kg (n=12) 1.5 mg/kg (n=14) Placebof (n=31) 0.25 mg/kg (n=14) 1 mg/kgf (n=32) 3 mg/kgf (n=33) 6 mg/kg (n=15) VLDL/Chylomicron Particles (nmol/L) 32.4c -7.6d -51.3cd -32.8cd -44.3cd -11.9 44.4 -0.74 -31.1 -31.0 LDL Particles (nmol/L) -1.3 -17.8cd -51.2cd -56.6cd -59.0cd 0.2 -12.4 -44.6cd -47.3cd -57.4cd Small LDL Particles (nmol/L) 8.5 -9.3 -57.6cd -50.9cd -68.5cd 14.3 -13.1d -42.1cd -54.6cd -58.8cd HDL Particles (umol/L) 3.9 11.1c 8.3c 9.3c 14.8cd -0.8 0.9 5.8cd 9.5cd 11.9cd VLDL Particle Size (nm) 7.8 7.5 12.1c 15.6c 12.4c 9.1c 3.9 1.4d 4.8 10.2c HDL Particle Size (nm) 0.6 0.8 1.0 1.8c 1.5c -0.5 0.3 0.8cd 1.0cd 0.3 LDL Particle Size (nm) -1.2 -0.4 1.6cd 0.3 1.1d -0.8 0.7 1.5cd 2.1cd 2.8cd a. Day 36 and Day 71 were two weeks after last dose in respective studies; b. obtained from ANCOVA model on the CFB with baseline levels as an covariant and treatment as a factor; c. p-Value for % CFB < 0.05; d. p-Value for % CFB vs Placebo < 0.05; e. Number of treated subjects with both baseline and Day 36 or Day 71 data available for analysis; f. Pooled data from Study #2 and #3.</abstract><cop>New York</cop><pub>Elsevier Limited</pub><doi>10.1016/S0735-1097(13)61387-X</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0735-1097 |
| ispartof | Journal of the American College of Cardiology, 2013-03, Vol.61 (10), p.E1387 |
| issn | 0735-1097 1558-3597 |
| language | eng |
| recordid | cdi_proquest_journals_1673886287 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via ScienceDirect (Elsevier); Alma/SFX Local Collection |
| subjects | Atoms & subatomic particles Cardiology Cholesterol Low density lipoprotein Particle size Studies |
| title | EFFECTS OF RN316 (PF-04950615), A HUMANIZED IGG2[delta]A MONOCLONAL ANTIBODY BINDING PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9, ON LIPOPROTEIN PARTICLES IN HYPERCHOLESTEROLEMIC SUBJECTS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T03%3A19%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=EFFECTS%20OF%20RN316%20(PF-04950615),%20A%20HUMANIZED%20IGG2%5Bdelta%5DA%20MONOCLONAL%20ANTIBODY%20BINDING%20PROPROTEIN%20CONVERTASE%20SUBTILISIN%20KEXIN%20TYPE%209,%20ON%20LIPOPROTEIN%20PARTICLES%20IN%20HYPERCHOLESTEROLEMIC%20SUBJECTS&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Wan,%20Hong&rft.date=2013-03-12&rft.volume=61&rft.issue=10&rft.spage=E1387&rft.pages=E1387-&rft.issn=0735-1097&rft.eissn=1558-3597&rft_id=info:doi/10.1016/S0735-1097(13)61387-X&rft_dat=%3Cproquest%3E3657613811%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1673886287&rft_id=info:pmid/&rfr_iscdi=true |